Germline variants in cancer predisposition genes were associated with worse event-free and overall survival in patients with neuroblastoma.
ERC-USA announced that the FDA recommended the early termination of a phase 2 clinical trial of ERC1671 to treat patients with recurrent or progressive glioblastoma and pursue a randomized confirmatory phase 3 trial.
The FDA granted fast track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma with unmethylated O6-Methylguaninemethyltransferase promoter status who have completed initial radiation with concomitant temozolomide.
Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone.
A population-based analysis found that racial and ethnic disparities in childhood central nervous system tumor survival seem to have their roots at least partially in post-diagnosis factors, possibly due to the lack of access to high quality care, leading to poorer overall outcomes.
The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.
The key to predicting when liquid biopsy would produce clinically actionable information is the ability to image the blood brain barrier and macrophages, according to researchers.
The results presented in this study indicated that neurosurgeons may need to change how they approach tumor removal and, when safe, include non-contrast-enhancing tumor during resection to achieve maximal resection.
These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.
A perioperative study confirmed brain penetrance and robust biomarker suppression in patients with low-grade glioma with an IDH1 mutation.